N'-cyano-2,2-dimethylpropanamidine | 69135-78-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N'-cyano-2,2-dimethylpropanamidine
• 英文别名: N-cyano-2,2-dimethyl-propionamidine；N'-cyano-2,2-dimethylpropanimidamide
• CAS: 69135-78-0
• 化学式: C₆H₁₁N₃
• mdl: MFCD18839910
• 分子量: 125.173
• InChiKey: WSDCPPVGNSPFMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  62.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N'-cyano-2,2-dimethylpropanamidine 在 五氯化磷 、 溶剂黄146 作用下， 以 苯 为溶剂， 生成 4-tert-butyl-2,6-dichloro-1,2-dihydro-[1,3,5,2]triazaphosphinine 2-oxide
  参考文献：
  名称：

  Kornuta,P.P. et al., Journal of general chemistry of the USSR, 1978, vol. 48, p. 2015 - 2018

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-二甲基丙亚胺盐酸 、 sodium cyanamide 以 水 为溶剂， 反应 4.0h， 以51%的产率得到N'-cyano-2,2-dimethylpropanamidine
  参考文献：
  名称：

  [EN] MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME
  [FR] COMPOSITIONS DE LUTTE CONTRE LES MOUSTIQUES VECTEURS, MÉTHODES ET PRODUITS L'UTILISANT

  摘要：

  这项发明涉及使用某种甲氧基丙烯酸酯化合物来控制蚊子，以及包括一种明确定义的甲氧基丙烯酸酯化合物的矢量控制溶液，特别是该发明涉及一种基质，一种用于控制蚊子的包括一种明确定义的甲氧基丙烯酸酯化合物的组合物，以及某些甲氧基丙烯酸酯化合物。

  公开号：

  WO2016193267A1

文献信息

• ALPHA-5 BETA-1 INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20210171455A1

  公开（公告）日：2021-06-10

  The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

  该披露提供了包括alpha-5 beta-1抑制剂、含有alpha-5 beta-1抑制剂的药物组合物、使用alpha-5 beta-1抑制剂治疗疾病的方法，以及制备alpha-5 beta-1抑制剂的过程等内容。
• OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2
  申请人：Janssen Pharmaceutica NV

  公开号：US20140024646A1

  公开（公告）日：2014-01-23

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , R 4 , R 5 , Z 1 and Z 2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涉及公式（I）的化合物，其中：R1、R2、R3、R4、R5、Z1和Z2如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、失调或疾病的方法，其中所述综合症、失调或疾病是II型糖尿病、肥胖症和哮喘。本发明还涉及一种通过给哺乳动物注射公式（I）至少一种化合物的治疗有效剂量来抑制CCR2活性的方法。
• Alpha-5 beta-1 inhibitors
  申请人：The Regents of the University of California

  公开号：US11530180B2

  公开（公告）日：2022-12-20

  The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.

  本公开特别提供了α-5 β-1抑制剂、包含α-5 β-1抑制剂的药物组合物、使用α-5 β-1抑制剂治疗疾病的方法以及制造α-5 β-1抑制剂的工艺。
• MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME
  申请人：Syngenta Participations AG

  公开号：EP3302056A1

  公开（公告）日：2018-04-11
• ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE
  申请人：Lee Seung-Yub

  公开号：US20110053901A1

  公开（公告）日：2011-03-03

  Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).